Healthcare / Medical DevicesShanghai
$13.16
+0.55 (+4.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $179.6M · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-5.1%
↓Gross Margin
26.6%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.3%
FCF CAGR
—
FCF margin
-26.1%
FCF / Net income
1.54x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.35B · net income $-227.9M · FCF $-351.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.35B | $1.35B | $1.52B | $1.24B | $1.12B |
| Net Income | $-227.9M | $-227.9M | $157.4M | $188.5M | $175.4M |
| EBITDA | $-254.0M | $-254.0M | $207.4M | $251.0M | $228.6M |
| EPS | -0.32 | -0.32 | 0.22 | 0.27 | 0.27 |
| Gross Margin | 26.6% | 26.6% | 36.6% | 42.1% | 44.1% |
| Operating Margin | -20.3% | -20.3% | 7.5% | 8.1% | 12.0% |
| Net Margin | -16.9% | -16.9% | 10.3% | 15.2% | 15.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 5.41 | 5.41 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-351.0M | $-351.0M | $179.6M | $191.1M | $171.4M |
| Returns | |||||
| ROE | -5.1% | -5.1% | 3.3% | 4.0% | 3.8% |
| Valuation | |||||
| P/E | — | — | 63.18 | 65.30 | 72.81 |
| EV/EBITDA | — | — | 30.74 | 35.42 | 41.77 |
| P/B | 2.10 | 2.10 | 2.09 | 2.61 | 2.77 |
| Growth & Yield | |||||
| Revenue Growth | -11.6% | -11.6% | 23.3% | 10.3% | — |
| EPS Growth | -245.5% | -245.5% | -18.5% | 0.0% | — |
| Dividend Yield | 1.0% | 1.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.6%
Start / end P/E
n/dx → n/dx
EPS bridge
0.22 → -0.32
Residual
-25.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.